Clinical Trial Update: A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety and immunogenicity of STR-V003 RSV vaccine in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• STR-V003

Snippet

Sponsor: Starna Therapeutics | Conditions: Respiratory Syncytial Virus Infections | Phase 1, Phase 2 | Status: UNKNOWN